



# R&D is in our Deoxyribonucleic acid.

While biotechnology companies and CROs are no strangers to R&D, few fully understand the complexities of the UK Government's R&D tax credit scheme and so end up missing out on this potentially lucrative source of additional funding.

**W**

*We could not have done what Jumpstart achieved on our own. The substantial body of work that was written up in our technical report was excellent. We might have got some of the way but certainly nowhere near as far and we would not have got it right first time.*

DR JO OLIVER  
AVANTICELL SCIENCE

**Get it right and you have the basis of a potentially significant claim. Get it wrong, as a lot of life sciences companies do, and you could end up with a swarm of HMRC inspectors buzzing around your head.**

●● As the UK's leading R&D tax relief specialist, let us share a few of the secrets to successful claims with you.

**DON'T UNDERESTIMATE YOUR UPFRONT COSTS**

This applies to all biotech, but pharma in particular where the time taken to get from first idea to market placement of a new drug can be enormous, along with the associated costs. For fear of over-claiming, traditional tax advisors typically take the 'safe' route of advising clients that the time spent at these very early stages isn't eligible, when in fact it is.

**IT'S OK TO FAIL**

No one likes a research project to fail but from an R&D tax relief perspective, this is often a sign of eligibility. This applies to all areas of biotech, but especially animal breeding where the considerable time and effort devoted to genetic analysis of agriculturally important organisms or phenotypes doesn't always pay off, at least not in project terms. The good news is that the same technical difficulty that caused the project to fail could also form the basis of a significant claim.

**THE SAME BUT DIFFERENT**

If you're involved in pilot production, there are a few more things you should know. Diagnostic companies that produce pilot assay kits,

reagents or solutions, for example, can't claim for lost production or opportunity costs, but can claim for the staff time, raw materials, subcontractors, software and utilities that go into the development and

testing of these products. It's subtleties like this that can make all the difference between a successful claim

and one that sparks an HMRC enquiry.

**GROUNDBREAKING OR JUST RAKING OVER OLD GROUND?**

It doesn't matter how intricate or tailored the final result may be. Simply reconfiguring an existing IT package doesn't constitute R&D in the eyes of HMRC. Medical devices companies need to be especially wary of this, but

it applies to the whole of the biotech sector.

**PARTNERSHIP IS THE WAY TO GO**

The key point to take out of all these examples is that specialist knowledge is key. With a proven track record of making literally hundreds of successful claims for biotech and contract research organisations, Jumpstart represents a simple and effective way to boost much needed funding.

Isn't it time you joined other biotech companies and CROs in securing your share of the £16.3bn of R&D tax relief already claimed since the start of the scheme?

**£16.5bn**  
The amount of R&D tax relief claimed by UK businesses since the scheme was launched

For a free R&D tax credit consultation and analysis of the potential returns you might expect contact us on 0333 920 0598 or at [helpinghand@jumpstartuk.co.uk](mailto:helpinghand@jumpstartuk.co.uk)

